Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

20260 citationsJournal Articlegold Open Access

Authors

N. Girard · Université de Versailles Saint-Quentin-en-Yvelines

J. Bar · Sheba Medical Center

P. Baas · Leiden University Medical Center

C. Chouaid · Hôpital Intercommunal de Créteil

D.C. Christoph · Evangelisches Krankenhaus Königin Elisabeth Herzberge

J.K. Field · University of Liverpool

R. Fietkau

Abstract

PACIFIC-R provides mature data on OS and rwPFS from a large, real-world cohort, supporting consolidation durvalumab as a standard of care in this setting.

Topics & Keywords

Lung Cancer Treatments and Mutations Gastric Cancer Management and Outcomes Lung Cancer Research Studies

Publication Details

Published in: ESMO Open

Volume 11, Issue 2, pp. 106070-106070

DOI: 10.1016/j.esmoop.2026.106070

Field-Weighted Citation Impact: 0.00

Command Palette

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Authors

Abstract

Topics & Keywords

Publication Details